Understanding the pharmacokinetics of Coartem®

Malaria Journal

Volumn 8, Issue SUPPL. 1, 2009, Pages

  Djimdé, Abdoulaye ^a   Lefèvre, Gilbert ^b  

^a UNIVERSITY OF BAMAKO   (Mali)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; DIHYDROARTEMISININ; KETOCONAZOLE; LOPINAVIR PLUS RITONAVIR; MEFLOQUINE; QUININE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEVELOPMENT; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALARIA; MAXIMUM PLASMA CONCENTRATION; MORBIDITY; POLYMERASE CHAIN REACTION; PREGNANCY; SINGLE DRUG DOSE; TABLET FORMULATION; TREATMENT FAILURE; BLOOD; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG INTERACTION; REVIEW;

ANTIMALARIALS; ARTEMISININS; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG INTERACTIONS; ETHANOLAMINES; FLUORENES; HUMANS;

EID: 70350004833     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-8-S1-S4     Document Type: Article

References (27)

1. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. NJ White M van Vugt F Ezzet, Clin Pharmacokinet 1999 37 105 125 10.2165/00003088-199937020-00002 10496300
2. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. F Ezzet R Mull J Karbwang, Br J Clin Pharmacol 1998 46 553 561 9862244 10.1046/j.1365-2125.1998.00830.x (Pubitemid 28522119)
3. Preventing antimalarial drug resistance through combinations. NJ White, Drug Resistance Updates 1998 1 3 9 10.1016/S1368-7646(98)80208-2 17092790
4. Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. G Kokwaro L Mwai A Nzila, Expert Opin Pharmacother 2007 8 75 94 10.1517/14656566.8.1.75 17163809
5. A clinical and pharmacokinetic trial of six doses of artemether- lumefantrine for multidrug-resistant plasmodium falciparum malaria in Thailand. G Lefèvre S Looareesuwan S Treeprasertsuk S Krudsood U Silachamroon I Gathmann R Mull R Bakshi, Am J Trop Med Hyg 2001 64 247 256 11463111
6. The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. R McGready K Stepniewska N Lindegardh EA Ashley Y La P Singhasivanon NJ White F Nosten, Eur J Clin Pharmacol 2006 62 1021 1031 10.1007/s00228-006-0199-7 17053895
7. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. F Ezzet M van Vugt F Nosten S Looareesuwan NJ White, Antimicrob Agents Chemother 2000 44 697 704 10681341 10.1128/AAC.44.3.697-704. 2000 (Pubitemid 30117964)
8. Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet®) with concomitant administration of ketoconazole in healthy subjects. G Lefèvre P Carpenter C Souppart H Schmidli M McLean D Stypinski, Br J Clin Pharmacol 2002 54 485 492 12445027 10.1046/j.1365-2125.2002.01696.x (Pubitemid 35356874)
9. Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria. EA Ashley K Stepniewska N Lindegårdh R McGready A Annerberg R Hutagalung T Singtoroj G Hla A Brockman S Proux J Wilahphaingern P Singhasivanon NJ White F Nosten, Trop Med Int Health 2007 12 201 208 17300626
10. How much fat is necessary to optimize lumefantrine oral bioavailability? EA Ashley K Stepniewska N Lindegårdh A Annerberg A Kham A Brockman P Singhasivanon NJ White F Nosten, Trop Med Int Health 2007 12 195 200 17300625
11. Exposure to lumefantrine in infants and children receiving artemether-lumefantrine for uncomplicated malaria: impact of African diet components. S Borrmann WM Sallas A-C Marrast G Lefèvre SE Kern, American Society of Tropical Medicine and Hygiene Annual Meeting, 7-11 December 2008, New Orleans, USA
12. The content of African diets is adequate to achieve optimal efficacy with fixed-dose artemether-lumefantrine: a review of the evidence. ZG Premji S Abdulla B Ogutu A Ndong CO Falade I Sagara N Mulure O Nwaiwu G Kokwaro, Malar J 2008 7 244 19032767 10.1186/1475-2875-7-244
13. Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomized trial. P Piola C Fogg F Bajunirwe S Biraro F Grandesso E Ruzagira J Babigumira I Kigozi J Kiguli J Kyomuhendo L Ferradini W Taylor F Checchi JP Guthmann, Lancet 2005 365 1467 1473 10.1016/S0140-6736(05)66416-1 15850630
14. Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetics and dosage-related findings from a clinical trial in Uganda. F Checchi P Piola P Fogg F Bajunirwe S Biraro F Grandesso E Ruzagira J Babigumira I Kigozi J Kiguli J Kyomuhendo L Ferradini WR Taylor, Malar J 2006 5 59 16854236 10.1186/1475-2875-5-59 (Pubitemid 44252727)
15. Data on file, Novartis Pharma AG. Study CCOA566B2106.
16. Coartem® Prescribing Information, Novartis Pharmaceuticals Corporation. Updated April 2009.
17. An integrated assessment of the clinical safety of artemether- lumefantrine: a new oral fixed-dose combination antimalarial drug. R Bakshi I Hermeling-Fritz I Gathmann E Alteri, Trans R Soc Trop Med Hyg 2000 94 419 424 10.1016/S0035-9203(00)90126-3 11127248
18. Data on file, Novartis Pharma AG. Study CCOA566A2403.
19. Efficacy and safety of artemether-lumefantrine dispersible tablet in African infants and children with uncomplicated malaria: a randomised, investigator-blinded, multi-centre comparison with the crushed commercial tablet. A Abdulla I Sagara S Borrmann U D' Alessandro R Gonzlez M Hamel B Ogutu A Mårtensson J Lyimo H Maiga P Sasi A Nahum Q Bassat E Juma L Otieno A Björkman HP Beck K Andriano M Cousin G Lefèvre D Ubben Z Premji, The Lancet 2008 372 1819 1827 10.1016/S0140-6736(08)61492-0
20. Early development of the new artemether-lumefantrine dispersible tablet: palatability and pharmacokinetics in healthy volunteers. G Lefèvre S Abdulla J Lyimo A Agyemang C Reynolds S Pascoe S Fitoussi C-M Yeh M Nuortti G-J Rivière R Séchaud, American Society of Tropical Medicine and Hygiene Annual Meeting, 7-11 December 2008, New Orleans, USA
21. Pharmacokinetic interaction trial between co-artemether and mefloquine. G Lefèvre M Bindschedler F Ezzet N Schaeffer I Meyer MS Thomsen, Eur J Pharm Sci 2000 10 141 151 10.1016/S0928-0987(00)00060-9 10727880
22. Interaction trial between artemether-lumefantrine (Riamet) and quinine in healthy subjects. G Lefèvre P Carpenter C Souppart H Schmidli JM Martin A Lane C Ward D Amakye, J Clin Pharmacol 2002 42 1147 1158 12362930
23. World Health Organization, Guidelines for treatment of malaria Geneva: World Health Organization 2006
24. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. P German S Parikh J Lawrence G Dorsey P Rosenthal D Havlir E Charlebois W Hanpithakpong N Lindegardh FT Aweeka, J Acquir Immune Defic Syndr 2009 51 424 429 10.1097/QAI.0b013e3181acb4ff 19506482
25. Induction effects of ritonavir: implications for drug interactions. MM Foisy EM Yakiwchuk CA Hughes, Ann Pharmacother 2008 42 1048 59 10.1345/aph.1K615 18577765
26. Simplified antimalarial therapeutic monitoring: using the day-7 drug level? NJ White K Stepniewska K Barnes RN Price J Simpson, Trends Parasitol 2008 24 159 163 10.1016/j.pt.2008.01.006 18353727
27. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. RN Price AC Uhlemann M van Vugt A Brockman R Hutagalung S Nair D Nash P Sinhasivanon TJC Anderson S Krishna NJ White F Nosten, Clin Infect Dis 2006 42 1570 1577 10.1086/503423 16652314